CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

The promise of a one-and-done CRISPR in­fu­sion is be­gin­ning to look more re­al than ever.
On Thurs­day, In­tel­lia Ther­a­peu­tics an­nounced that an ex­per­i­men­tal gene edit­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.